Nasal cells drive differences in cold severity

Scientists have discovered that the body's rapid response in nasal cells largely determines whether a rhinovirus infection leads to a mild cold or more severe symptoms. Using lab-grown human nasal tissue, researchers showed how interferons coordinate defenses to contain the virus early. The findings, published January 19 in Cell Press Blue, emphasize the role of host responses over viral traits alone.

Rhinovirus, the leading cause of common colds, triggers an immediate defense in the nasal passages upon entry. Cells lining the nose activate antiviral mechanisms to limit the virus's spread, according to a study led by Ellen Foxman of Yale School of Medicine. This early reaction often decides if symptoms develop and their intensity, particularly in individuals with asthma or chronic lung conditions.

To investigate, the team developed organoids from human nasal stem cells, cultured for four weeks with air exposure on the upper surface. This created a multilayered tissue mimicking the nasal lining, complete with mucus-producing cells and ciliated cells that clear debris. "This model reflects the responses of the human body much more accurately than the conventional cell lines used for virology research," Foxman noted, highlighting its value for studying a human-specific virus like rhinovirus.

Experiments revealed that upon detection, infected cells release interferons—proteins that alert nearby healthy cells to bolster defenses against viral replication. A swift interferon response confines the infection, preventing symptoms. Blocking this pathway allowed the virus to proliferate, damaging tissue and even killing organoids in some cases. "Our experiments show how critical and effective a rapid interferon response is in controlling rhinovirus infection, even without any cells of the immune system present," said first author Bao Wang.

If the virus evades initial controls and replicates, it activates sensors prompting excessive mucus production and inflammation in both infected and uninfected cells. These responses contribute to airway issues and breathing difficulties. The researchers suggest targeting such pathways could yield treatments that enhance defenses while curbing harmful inflammation.

While the model lacks the full diversity of human tissues, including immune cells, it underscores that host factors are pivotal in illness outcomes. "Our study advances the paradigm that the body's responses to a virus, rather than the properties inherent to the virus itself, are hugely important in determining whether or not a virus will cause illness and how severe the illness will be," Foxman concluded. Future studies will explore additional cell interactions and environmental influences.

관련 기사

Realistic depiction of a long COVID patient experiencing fatigue and breathing difficulties, overlaid with highlighted CD14+ monocytes (LC-Mo state) and inflammatory markers from recent immune study.
AI에 의해 생성된 이미지

Study links a distinct CD14+ monocyte state to fatigue and breathing symptoms in long COVID

AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨

Researchers analyzing immune cells from people with long COVID have identified a distinct molecular state in CD14+ monocytes—labeled “LC-Mo”—that was more prevalent among patients whose initial COVID-19 illness was mild to moderate and that tracked with reported fatigue and respiratory symptoms, along with higher levels of inflammatory signaling molecules in blood plasma.

Researchers at Stanford Medicine have created an experimental nasal spray vaccine that protects mice against multiple respiratory threats, including COVID-19, flu, bacterial pneumonia, and allergens. The vaccine activates the lungs' innate immune system for months, offering broad defense without targeting specific pathogens. Published in Science on February 19, the study suggests potential for human trials soon.

AI에 의해 보고됨

Researchers at the University of California, San Francisco have identified how aging lungs contribute to severe flu and COVID-19 outcomes in older adults. Their study shows that lung fibroblasts trigger excessive inflammation, forming damaging clusters of immune cells. The findings, published in Immunity on March 27, suggest potential new treatments.

Researchers at UCLA have identified senescent immune cells, dubbed 'zombie' cells, that accumulate in aging livers and contribute to fatty liver disease. By eliminating these cells in mice, the team reversed liver damage and reduced body weight, even on an unhealthy diet. The findings, published in Nature Aging, suggest similar mechanisms may drive human liver conditions.

AI에 의해 보고됨

Scientists at McMaster University and the Hospital for Sick Children in Canada have discovered that oligodendrocytes, cells typically supporting nerve function, aid the growth of glioblastoma by sending signals to tumor cells. Blocking this communication slowed tumor progression in lab models. The findings suggest an existing HIV drug, Maraviroc, could be repurposed for treatment.

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부